Sterling Investment Advisors (Pennsylvania)’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-92
Closed 555
2020
Q4
$0 Hold
92
﹤0.01% 492
2020
Q3
$0 Buy
+92
New +$263 ﹤0.01% 478

Other funds holding BMY.RT

Sterling Investment Advisors (Pennsylvania)'s BMY.RT Position: Q1 2021 in Review

Sterling Investment Advisors (Pennsylvania) sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 92 shares.

Sterling Investment Advisors (Pennsylvania) first reported a position in BMY.RT in Q3 2020 and held it in 2 quarters. The position peaked at $0 in Q4 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Sterling Investment Advisors (Pennsylvania) reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Sterling Investment Advisors (Pennsylvania) sold 92 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
  • Sterling Investment Advisors (Pennsylvania) first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q3 2020 and held it in 2 quarters.
  • Sterling Investment Advisors (Pennsylvania)'s Bristol-Myers Squibb Company Contingent Value Rights position peaked at $0 in Q4 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Sterling Investment Advisors (Pennsylvania)'s 13F filing for Q1 2021, filed 4 May 2021.